Heteroaryl amides as inhibitors of protein aggregation
AssigneeUCB Biophama SRL
InventorsWolfgang Wrasidlo, Emily M. Stocking
Life of this patent
Estimating the term…
Abstract
The present invention relates to certain heteroaryl amide compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer and melanoma.
Claims37
A compound of Formula (I):
- wherein
- R1 is H, halo, C1-4alkyl, or —CF3;
- R2 is —CF3 or C1-4alkyl unsubstituted or substituted with halo or —CF3;
- A is a 5-membered heteroaryl ring with two or three heteroatom ring atoms selected from the group consisting of N, O, and S, and wherein the 5-membered heteroaryl ring is attached to
- and Y via two non-adjacent carbon ring atoms;
- Y is absent or is C1-4alkylene;
- where when Y is absent, R3 and R4 taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring, unsubstituted or substituted with C1-4alkyl;
- and
- when Y is C1-4alkylene, R3 and R4 taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring, unsubstituted or substituted with C1-4alkyl;
- or R3 and Y taken together with the nitrogen to which R3 is attached form a monocyclic heterocycloalkyl ring, and R4 is H or C1-4alkyl;
- or a pharmaceutically acceptable salt thereof.
A compound selected from the group consisting of:
- and pharmaceutically acceptable salts thereof.
A compound selected from the group consisting of:
- and pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.